Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus

Fig. 4

a Event-free and b MACE-free survival curves of patients without diabetes mellitus (black line), with T2D and baseline HbA1c ≤ 54 mmol/mol (dashed grey line), and with T2D and baseline HbA1c of > 54 mmol/mol (solid grey line). MACE was defined as composite endpoint including non-fatal myocardial infarction (STEMI or NSTEMI), indication of urgent need for coronary intervention, non-fatal stroke or TIA, and cardiovascular death

Back to article page